Antidiabetic effect of oral supplementation with Caulerpa racemosa powder
Algae are known for their high nutritional value and the presence of bioactive compounds with anti-diabetic activity. In this study, the effects of oral supplementation with the whole powdered green alga Caulerpa racemosa was assessed on biochemical and organic parameters in rat model of type 2 diabetes. Type 2 diabetes model (DM) was induced by high fat diet (HFD) (5.75 kcal/g) combined to streptozotocin injection (35 mg/kg). The DM-C500 and DM-C1000 groups were maintained on HFD and supplemented orally during four weeks with powdered C. racemosa at 500 and 1000 mg/kg of body weight, respectively. The DM-C0 group was fed with HFD without C. racemosa supplementation. All the experimental rats were maintained on HFD during the 30 days of experiment. C. racemosa at 500 mg/kg improved fasting glycaemia and glucose tolerance. The IPGTT test revealed a decrease (p<0.05) in the fasting glycaemia recorded at the 120th min from day 0 (534 ± 38.88 mg/dL) to day 30 (326 ± 63.05 mg/dL). C. racemosa supplementation prevented liver lipid peroxidation in DM-C500 and DM-C1000 group (12.94 ± 2.20 and 10.48 ± 1.15 nmol MDA/g, respectively) compared to DM-C0 group (35.49 ± 2.30 nmol MDA/g). Caulerpa racemosa at 500 mg/kg, and relatively at 1000 mg/kg, alleviated pancreatic, liver and renal tissue damages compared to DM-C0 groups which displayed injuries in their histological sections. Caulerpa racemosa oral supplementation could represent a possible natural approach to prevent organic and metabolic disorders related to type 2 diabetes.
2. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2021; 27: 269-273.
3. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab. Care. 1997; 20: 1183-1197.
4. Marcovecchio ML, Lucantoni M, Chiarelli F. Role of chronic and acute hyperglycemia in the development of diabetes complications. Diabetes Technol Ther. 2011; 13: 389-394.
5. Hallberg S J, Gershuni VM, Hazbun TL, Athinarayanan SJ. Reversing Type 2 Diabetes: A Narrative Review of the Evidence. Nutrients. 2019; 11: 766.
6. WHO. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine, WHO. 2000; 27-36.
7. Sharifuddin Y, Chin YX, Lim PE, Phang SM. Potential bioactive compounds from seaweed for diabetes management. Mar Drugs. 2015; 13: 5447-5491.
8. Unnikrishnan PS, Suthindhiran K, Jayasri MA. Antidiabetic potential of marine algae by inhibiting key metabolic enzymes. Front Life Sci. 2015; 2: 148-159.
9. Bocanegra A, Bastida S, Benedi J, Ródenas S, Muniz FJS. Characteristics and nutritional and cardiovascular-health properties of seaweeds. J Med Food. 2009; 12: 236-258.
10. Cherry P, O’Hara C, Magee PJ, McSorley EM, Allsopp PJ. Risks and benefits of consuming edible seaweeds. Nutr Rev. 2019; 77: 307-329.
11. Lange KW, Hauser J, Nakamura Y, Kanaya S. Dietary seaweeds and obesity. Food Sci Hum Well. 2015; 4: 87-96.
12. Aroyehun AQB, Abdul Razak S, Palaniveloo K, Nagappan T, Rahmah NSN, et al. Bioprospecting cultivated tropical green algae, Caulerpa racemosa (Forsskal) J. Agardh: a perspective on nutritional properties, antioxidative capacity and anti-diabetic potential. Foods. 2020; 9: 1313.
13. Teixeira VL, Rocha FD, Houghton PJ, Kaplan MA, Pereira RC. Alpha-amylase inhibitors from Brazilian seaweeds and their hypoglycemic potential. Fitoterapia. 2007; 78: 35-36.
14. Agatonovic-Kustrin S, Morton DW. High-performance thin-layer chromatography HPTLC-direct bioautography as a method of choice for alpha-amylase and antioxidant activity evaluation in marine algae. J Chromatogr. 2017; 1530: 197-203.
15. Parveen K, Khan MR, Siddiqui WA. Antidiabetic effects afforded by Terminalia arjuna in high fat-fed and streptozotocin-induced type 2 diabetic rats. Int J Diabetes Metab. 2011; 19: 23-33.
16. Council of European Communities. Council instructions about the protection of living animals used in scientific investigations. Off J Eur Communities. 1986; 358: 1-28.
17. Genot C. Some factors influencing TBA test. Annual report of the Vth PCRD EU project: Dietary treatment and oxidative stability of muscle and meat products: nutritive value, sensory quality and safety. (Diet-ox) AIR III-CT-92-1577, 1997.
18. Parveen K, Khan MR, Mujeeb M, Siddiqui WA. Protective effects of Pycnogenol on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats. Chem Biol Interact. 2010; 186: 196-227.
19. Sahin K, Tuzcu M, Orhan C, Sahin N, Kucuk O, et al. Anti-diabetic activity of chromium picolinate and biotin in rats with type 2 diabetes induced by high-fat diet and streptozotocin. Br J Nutr. 2013; 110: 197-205.
20. Asrafuzzaman M, Cao Y, Afroz R, Kamato D, Gray S, et al. Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of type 2 diabetes. Biomed Pharmacother. 2017; 89: 1242-1251.
21. Vatandoust N, Rami F, Salehi AR, Khosravi S, Dashti G, et al. Novel high-fat diet formulation and streptozotocin treatment for induction of prediabetes and type 2 diabetes in rats. Adv Biomed Res. 2018; 7: 107.
22. Belkacemi L, Belalia M, Djendara AC, Bouhadda Y. Antioxidant and antibacterial activities and identification of bioactive compounds of various extracts of Caulerpa racemosa from Algerian coast. Asian Pac J Trop Biomed. 2020; 10: 87-94.
23. Balamurugan R, Duraipandiyan V, Ignacimuthu S. Antidiabetic activity of γ-sitosterol isolated from Lippia nodiflora L. in streptozotocin induced diabetic rats. Eur J Pharmacol. 2011; 667: 410-418.
24. Murakami S, Hirazawa C, Ohya T, Yoshikawa R, Mizutani T, et al. The Edible Brown Seaweed Sargassum horneri (Turner) C. Agardh Ameliorates High-Fat Diet-Induced Obesity, Diabetes, and Hepatic Steatosis in Mice. Nutrients. 2021; 8: 551.
25. Kumar SA, Magnusson M, Ward LC, Paul NA, Brown L. Seaweed Supplements Normalise Metabolic, Cardiovascular and Liver Responses in High-Carbohydrate, High-Fat Fed Rats. Mar Drugs. 2015; 13: 788-805.
26. Del Ben M, Polimeni L, Baratta F, Pastori D, Angelic F. The role of nutraceuticals for the treatment of non‐alcoholic fatty liver disease. Br J Clin Pharmacol. 2017; 83: 88-95.
27. Motshakeri M, Ebrahimi M, Goh YM, Othman HH, Hair-Bejo M, et al. Effects of brown seaweed (Sargassum polycystum) extracts on kidney, liver, and pancreas of type 2 diabetic rat model. Evid Based Complem Altern Med. 2014; 2014: 379407.
28. Rubido JCA. 2009. Liver function tests. In: Al Mahtab M, Eds. Liver: a complete book on hepato-pancreato-biliary diseases. India, Elsevier: 47-56.
29. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, et al. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000; 46: 2050-2068.
30. Ulla A, Alam MA, Sikder B, Sumi FA, Rahman MM, et al. Supplementation of Syzygium cumini seed powder prevented obesity, glucose intolerance, hyperlipidemia and oxidative stress in high carbohydrate high fat diet induced obese rats. BMC Complem Altern Med. 2017; 17: 289.
31. Fernando IPS, Sanjeewa KKA, Samarakoon KW, Lee WW, Kim HS, et al. Squalene isolated from marine macroalgae Caulerpa racemosa and its potent antioxidant and anti‐inflammatory activities. J Food Biochem. 2018; 42: 12628.
32. Ragavan B, Krishnakumari S. Antidiabetic effect of T. arjuna bark extract in alloxan induced diabetic rats. Indian J Clin Biochem. 2006; 21: 123-128.
33. Othman AI, Abdel-Ghaffar A, Mahmoud AM. Ketorolac- and warfarin-induced renal toxicity: ultrastructural and biochemical study. JOBAZ. 2019; 80: 36.
34. Cao M, Li Y, Famurewa AC, Olatunji OJ. Antidiabetic and nephroprotective effects of polysaccharide extract from the seaweed Caulerpa racemosa in high fructose-streptozotocin induced diabetic nephropathy. Diabetes Metab Syndr Obes. 2021; 14: 2121-2131.
This work is licensed under a Creative Commons Attribution 4.0 International License.